EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, ITeos Therapeutics's enterprise value is $-111.90 Mil.
ITeos Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.60 Mil. Therefore, ITeos Therapeutics's EV-to-Revenue for today is -8.88.
The historical rank and industry rank for ITeos Therapeutics's EV-to-Revenue or its related term are showing as below:
ITOS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -13.65 Med: -0.13 Max: 8.26
Current: -8.34
During the past 6 years, the highest EV-to-Revenue of ITeos Therapeutics was 8.26. The lowest was -13.65. And the median was -0.13.
ITOS's EV-to-Revenue is ranked better than 96.81% of 1035
companies
in the Biotechnology industry
Industry Median: 8.07
vs ITOS: -8.34
The historical data trend for ITeos Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ITeos Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, ITeos Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ITeos Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where ITeos Therapeutics's EV-to-Revenue falls into.
ITeos Therapeutics's current Enterprise Value is $-111.90 Mil.
ITeos Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITeos Therapeutics's share price for today is $11.80.
ITeos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITeos Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of ITeos Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
ITeos Therapeutics (ITeos Therapeutics) Business Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ITOS has been successfully added to your 